tiprankstipranks
Mallinckrodt public limited company (MNK)
NYSE MKT:MNK
US Market

Mallinckrodt public limited company (MNK) Stock Price & Analysis

10 Followers

MNK Stock Chart & Stats

Day’s Range$0.3 - $0.41
52-Week Range― - ―
Previous Close$0.4
Volume1.47K
Average Volume (3M)N/A
Market Cap
$1.70M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Nov 07, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

MNK FAQ

What was Mallinckrodt public limited company’s price range in the past 12 months?
Currently, no data Available
What is Mallinckrodt public limited company’s market cap?
Currently, no data Available
When is Mallinckrodt public limited company’s upcoming earnings report date?
Mallinckrodt public limited company’s upcoming earnings report date is Nov 07, 2023 which is 143 days ago.
    How were Mallinckrodt public limited company’s earnings last quarter?
    Mallinckrodt public limited company released its earnings results on Aug 09, 2023. The company reported -$56.652 earnings per share for the quarter, missing the consensus estimate of N/A by -$56.652.
      Is Mallinckrodt public limited company overvalued?
      According to Wall Street analysts Mallinckrodt public limited company’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Mallinckrodt public limited company pay dividends?
        Mallinckrodt public limited company does not currently pay dividends.
        What is Mallinckrodt public limited company’s EPS estimate?
        Mallinckrodt public limited company’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Mallinckrodt public limited company have?
        Currently, no data Available
        What happened to Mallinckrodt public limited company’s price movement after its last earnings report?
        Mallinckrodt public limited company reported an EPS of -$56.652 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -31.724%.
          Which hedge fund is a major shareholder of Mallinckrodt public limited company?
          Among the largest hedge funds holding Mallinckrodt public limited company’s share is Cyrus Capital Partners, L.P.. It holds Mallinckrodt public limited company’s shares valued at N/A.
            ---

            Company Description

            Mallinckrodt public limited company

            Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which includes innovative specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of revenue from the United States.
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            MannKind
            Teva Pharmaceutical
            Horizon Therapeutics
            GlaxoSmithKline
            Popular Stocks
            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis